4th Quarter - Termination
NVG, LLC for ALEXION PHARMACEUTICALS
Firm
Client
Income
$50,000
Expenses
—
Terminated
Dec 31, 2021
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Orphan Drug Tax Credit provisions in the Build Back Better Act (H.R. 5376).
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
| ANDREA LARUE | — |
Health Issues HCR
FDA - rare and orphan disease issues; Prescription drug coverage and payment policies; Medical innovation issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
| ANDREA LARUE | — |
Budget/Appropriations BUD
FY 2022 LHHS Appropriations report language on Wilson's Disease, Myasthenia Gravis; Neuromyelitis Optica Spectrum Disorder (NMOSD); Low volume DRG payments for rare disease therapies and home infusion.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.